Gregory L. Beatty

University of Pennsylvania — United States

Medicine · Health Sciences

48h-index15.6kcitations287works5.92yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Immunotherapy and Biomarkers(130), Pancreatic and Hepatic Oncology Research(112), Immune cells in cancer(58), CAR-T cell therapy research(43), Immunotherapy and Immune Responses(39)

Publications287 total

Sequential platinum and PARP Inhibition enhances PD1 immunotherapy efficacy in murine Brca2 mutated pancreatic cancer
Scientific Reports·2026Open Access
A dual diacylglycerol kinase (DGK) alpha/zeta inhibitor augments the activity of human tumor infiltrating lymphocytes in <i>in vivo</i> and <i>ex vivo</i> models
OncoImmunology·2025Open Access
Supplementary Data 2 from Treatment Response in First-Line Metastatic Pancreatic Ductal Adenocarcinoma Is Stratified By a Composite Index of Tumor Proliferation and CD8 T-Cell Infiltration
2025Open Access
Supplementary Data 1 from Treatment Response in First-Line Metastatic Pancreatic Ductal Adenocarcinoma Is Stratified By a Composite Index of Tumor Proliferation and CD8 T-Cell Infiltration
2025Open Access
Figure S1 from Nonredundant Immune Checkpoints Direct Therapeutic Resistance to Chemoimmunotherapy in Pancreatic Ductal Adenocarcinoma
2025Open Access
Figure S2 from Nonredundant Immune Checkpoints Direct Therapeutic Resistance to Chemoimmunotherapy in Pancreatic Ductal Adenocarcinoma
2025Open Access
Table S7 from Nonredundant Immune Checkpoints Direct Therapeutic Resistance to Chemoimmunotherapy in Pancreatic Ductal Adenocarcinoma
2025Open Access
Table S2 from Nonredundant Immune Checkpoints Direct Therapeutic Resistance to Chemoimmunotherapy in Pancreatic Ductal Adenocarcinoma
2025Open Access
Figure S4 from Nonredundant Immune Checkpoints Direct Therapeutic Resistance to Chemoimmunotherapy in Pancreatic Ductal Adenocarcinoma
2025Open Access
Figure S9 from Nonredundant Immune Checkpoints Direct Therapeutic Resistance to Chemoimmunotherapy in Pancreatic Ductal Adenocarcinoma
2025Open Access
Figure S3 from Nonredundant Immune Checkpoints Direct Therapeutic Resistance to Chemoimmunotherapy in Pancreatic Ductal Adenocarcinoma
2025Open Access
Figure S7 from Nonredundant Immune Checkpoints Direct Therapeutic Resistance to Chemoimmunotherapy in Pancreatic Ductal Adenocarcinoma
2025Open Access
Table S6 from Nonredundant Immune Checkpoints Direct Therapeutic Resistance to Chemoimmunotherapy in Pancreatic Ductal Adenocarcinoma
2025Open Access
Table S3 from Nonredundant Immune Checkpoints Direct Therapeutic Resistance to Chemoimmunotherapy in Pancreatic Ductal Adenocarcinoma
2025Open Access
Figure S5 from Nonredundant Immune Checkpoints Direct Therapeutic Resistance to Chemoimmunotherapy in Pancreatic Ductal Adenocarcinoma
2025Open Access
Data from Nonredundant Immune Checkpoints Direct Therapeutic Resistance to Chemoimmunotherapy in Pancreatic Ductal Adenocarcinoma
2025Open Access
Figure S6 from Nonredundant Immune Checkpoints Direct Therapeutic Resistance to Chemoimmunotherapy in Pancreatic Ductal Adenocarcinoma
2025Open Access
Figure S8 from Nonredundant Immune Checkpoints Direct Therapeutic Resistance to Chemoimmunotherapy in Pancreatic Ductal Adenocarcinoma
2025Open Access
Table S4 from Nonredundant Immune Checkpoints Direct Therapeutic Resistance to Chemoimmunotherapy in Pancreatic Ductal Adenocarcinoma
2025Open Access
Figure S10 from Nonredundant Immune Checkpoints Direct Therapeutic Resistance to Chemoimmunotherapy in Pancreatic Ductal Adenocarcinoma
2025Open Access
page 1 of 15Next →

Frequent Co-authors

Robert H. Vonderheide(13), Mark H. O’Hara(8), Whitney L. Gladney(7), Bruce L. Levine(7), Carl H. June(7), Drew A. Torigian(6), Jae W. Lee(6), Kristen B. Long(6), Gabriela Plesa(5), Kathleen Graham(5), Max M. Wattenberg(5), Peter J. O’Dwyer(4), Simon F. Lacey(4), Mingen Liu(4), Andrew D. Rhim(3), Ursina Teitelbaum(3), Carolyn E. Clark(3), Andrew R. Haas(3), Michael C. Soulen(3), Steven Μ. Albelda(3)